Apoptosis/Necroptosis Antibody Sampler Kit #92570
Product Information
Kit Usage Information
Protocols
- 3493: Western Blotting, Immunoprecipitation (Agarose), Immunofluorescence, Flow
- 4790: Western Blotting
- 7074: Western Blotting
- 7076: Western Blotting
- 9664: Western Blotting, Immunoprecipitation (Agarose), Immunohistochemistry (Paraffin), Immunofluorescence, Flow
- 9748: Western Blotting
- 14220: Western Blotting, Immunoprecipitation (Agarose)
- 14993: Western Blotting
- 65746: Western Blotting
- 91689: Western Blotting
Product Description
The Apoptosis/Necroptosis Antibody Sampler Kit provides an economical means of detecting markers for apoptosis and necroptosis. The kit contains enough primary antibody to perform at least two western blot experiments.
Specificity / Sensitivity
Each antibody in the Apoptosis/Necroptosis Antibody Sampler Kit detects endogenous levels of its target protein. MLKL (D2I6N) Rabbit mAb cross-reacts with a band at 130 kDa in some cell lines. Phospho-MLKL (Ser358) (D6H3V) Rabbit mAb may also react with MLKL when dually phoshorylated at Thr357 and Ser358. Caspase-3 (D3R6Y) Rabbit mAb detects full-length caspase-3 as well as the large subunit (p20) of caspase-3 resulting from cleavage during apoptosis. Cleaved Caspase-3 (Asp175) (5A1) Rabbit mAb detects endogenous levels of the large subunit of caspase-3 but does not detect full-length caspase-3 or other cleaved caspases. Cleaved Caspase-8 (Asp384) (11G10) Mouse mAb detects endogenous levels of the small fragment of caspase-8 resulting from cleavage at aspartic acid 384. The antibody does not cross-react with full length caspase-8. Caspase-8 (D35G2) Rabbit mAb detects endogenous levels of total caspase-8, including the p10 subunit of the activated protein. It may also cross-react with overexpressed levels of caspase-10.
Source / Purification
Monoclonal antibodies are produced by immunizing animals with synthetic peptides surrounding Leu190 of human RIP1, the carboxy terminus of human MLKL and human caspase-8, the amino-terminal sequence of p10 of human caspase-8, amino terminal residues adjacent to Asp175 of human caspase-3, a recombinant protein corresponding to the p20 subunit of caspase-3, and phosphopeptides surrounding human Ser166 of human RIP and Ser358 of human MLKL.
Background
Apoptosis is a regulated physiological process leading to cell death (1,2). Caspases, a family of cysteine acid proteases, are central regulators of apoptosis. Caspases are synthesized as inactive zymogens containing a pro-domain followed by large (p20) and small subunits (p10) that are proteolytically processed in a cascade of caspase activity. Initiator caspases (including 8, 9, 10, and 12) are closely coupled to proapoptotic signals. Once activated, these caspases cleave and activate downstream effector caspases (including 3, 6, and 7), which in turn cleave cytoskeletal and nuclear proteins like PARP, α-fodrin, DFF, and lamin A, and induce apoptosis. Cytochrome c released from mitochondria is coupled to the activation of caspase-9, a key initiator caspase. Apoptosis induced through the extrinsic mechanisms involving death receptors in the tumor necrosis factor receptor superfamily activates caspase-8. Activated caspase-8 cleaves and activates downstream effector caspases, such as caspase-1, -3, -6, and -7. Caspase-3 is a critical executioner of apoptosis, as it is either partially or totally responsible for the proteolytic cleavage of many key proteins, such as the nuclear enzyme poly (ADP-ribose) polymerase (PARP).
Necroptosis, a regulated pathway for necrotic cell death, is triggered by a number of inflammatory signals, including cytokines in the tumor necrosis factor (TNF) family, pathogen sensors such as toll-like receptors (TLRs), and ischemic injury (3,4). Necroptosis is negatively regulated by caspase-8 mediated apoptosis in which the kinase RIP/RIPK1 is cleaved (5). Furthermore, necroptosis is inhibited by a small molecule inhibitor of RIP, necrostatin-1 (Nec-1) (6). Research studies show that necroptosis contributes to a number of pathological conditions, and Nec-1 has been shown to provide neuroprotection in models such as ischemic brain injury (7). RIP is phosphorylated at several sites within the kinase domain that are sensitive to Nec-1, including Ser14, Ser15, Ser161, and Ser166 (8). Phosphorylation drives association with RIP3, which is required for necroptosis (9-11). Mixed lineage kinase domain-like protein (MLKL) is a pseudokinase that was identified as a downstream target of RIP3 in the necroptosis pathway (12). During necroptosis, RIP3 is phosphorylated at Ser227, which recruits MLKL and leads to its phosphorylation at Thr357 and Ser358 (12). Knockdown of MLKL through multiple mechanisms results in inhibition of necroptosis (13). Phosphorylation of MLKL during necroptosis leads to its oligomerization with pore formation that affects membrane integrity (14-17).
Necroptosis, a regulated pathway for necrotic cell death, is triggered by a number of inflammatory signals, including cytokines in the tumor necrosis factor (TNF) family, pathogen sensors such as toll-like receptors (TLRs), and ischemic injury (3,4). Necroptosis is negatively regulated by caspase-8 mediated apoptosis in which the kinase RIP/RIPK1 is cleaved (5). Furthermore, necroptosis is inhibited by a small molecule inhibitor of RIP, necrostatin-1 (Nec-1) (6). Research studies show that necroptosis contributes to a number of pathological conditions, and Nec-1 has been shown to provide neuroprotection in models such as ischemic brain injury (7). RIP is phosphorylated at several sites within the kinase domain that are sensitive to Nec-1, including Ser14, Ser15, Ser161, and Ser166 (8). Phosphorylation drives association with RIP3, which is required for necroptosis (9-11). Mixed lineage kinase domain-like protein (MLKL) is a pseudokinase that was identified as a downstream target of RIP3 in the necroptosis pathway (12). During necroptosis, RIP3 is phosphorylated at Ser227, which recruits MLKL and leads to its phosphorylation at Thr357 and Ser358 (12). Knockdown of MLKL through multiple mechanisms results in inhibition of necroptosis (13). Phosphorylation of MLKL during necroptosis leads to its oligomerization with pore formation that affects membrane integrity (14-17).
- Degterev, A. et al. (2003) Oncogene 22, 8543-67.
- Green, D.R. (1998) Cell 94, 695-8.
- Christofferson, D.E. and Yuan, J. (2010) Curr Opin Cell Biol 22, 263-8.
- Kaczmarek, A. et al. (2013) Immunity 38, 209-23.
- Lin, Y. et al. (1999) Genes Dev 13, 2514-26.
- Degterev, A. et al. (2008) Nat Chem Biol 4, 313-21.
- Degterev, A. et al. (2005) Nat Chem Biol 1, 112-9.
- Ofengeim, D. and Yuan, J. (2013) Nat Rev Mol Cell Biol 14, 727-36.
- Cho, Y.S. et al. (2009) Cell 137, 1112-23.
- He, S. et al. (2009) Cell 137, 1100-11.
- Zhang, D.W. et al. (2009) Science 325, 332-6.
- Sun, L. et al. (2012) Cell 148, 213-27.
- Wu, J. et al. (2013) Cell Res 23, 994-1006.
- Cai, Z. et al. (2014) Nat Cell Biol 16, 55-65.
- Chen, X. et al. (2014) Cell Res 24, 105-21.
- Wang, H. et al. (2014) Mol Cell 54, 133-46.
- Dondelinger, Y. et al. (2014) Cell Rep 7, 971-81.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.